Following the observation that the EWS-FLI1 genotype may serve as a biomarker for PARPi sensitivity, a clinical trial was initiated testing single-agent olaparib in Ewing’s sarcoma patients with recurrent disease, but clinical response endpoints were not met [24–27]. Here, FLI1 is linked to Ewing sarcoma.